Multiplex SNP Genotyping Using SWITCH: Sequence‐Specific Nanoparticle with Interpretative Toehold‐Mediated Sequence Decoding in Hydrogel. Issue 8 (19th December 2021)

• Record Type: Journal Article
• Authors: Choi, Woongsun; Park, Eunhye; Bae, Seojin; Choi, Kyung‐Hak; Han, Sangeun; Son, Kuk‐Hui; Lee, Do Young; Cho, Il‐Joo; Seong, Hyejeong; Hwang, Kyo Seon; Nam, Jwa‐Min; Choi, Jungkyu; Lee, Hyojin; Choi, Nakwon
• Is Part Of: Small. Volume 18:Issue 8(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-12-19
• Subjects: gold nanoparticles -- hydrogel microparticles -- magnetic microparticles -- multiplex single nucleotide polymorphism genotyping -- sandwich assays -- toehold‐mediated DNA displacement -- warfarin; Nanotechnology -- Periodicals; Nanoparticles -- Periodicals; Microtechnology -- Periodicals; 620.5
• DOI: 10.1002/smll.202105538
• Languages: English
• ISSNs: 1613-6810

Abstract

Abstract: Single nucleotide polymorphisms (SNPs) that can alter phenotypes of individuals play a pivotal role in disease development and, more importantly, responses to therapy. However, SNP genotyping has been challenging due to the similarity of SNP alleles and their low concentration in biological samples. Sequence‐specific nanoparticle with interpretative toehold‐mediated sequence decoding in hydrogel (SWITCH) for multiplex SNP genotyping is presented. The encoding with gold nanoparticle probes transduces each SNP target to ≈1000 invaders with prominently different sequences between wild and mutant types, featuring polymerase chain reaction (PCR)‐free amplification. Subsequently, the toehold‐mediated DNA replacement in hydrogel microparticles decodes the invaders via SNP‐specific fluorescence signals. The 4‐plex detection of the warfarin‐associated SNP targets spiked in commercially validated human serum (S1‐100ML, Merck) is successfully demonstrated with excellent specificity. This work is the first technology development presenting PCR‐free, multiplex SNP genotyping with a single reporting fluorophore, to the best of knowledge. Abstract : The SWITCH is the first development presenting polymerase chain reaction‐free, multiplex single nucleotide polymorphism genotyping with a single reporting fluorophore by a hybrid assay using inorganic and organic materials.